Market News (Page 1) - TendieTensor

Market News Page 1 of 178 • 4,450 articles

Autism Spectrum Disorder Market to Reach USD 4.07 Billion by 2033, Driven by Rising Awareness, Early Diagnosis & Advances in Personalized Therapeutics | SNS Insider

GlobeNewswire Inc. • Sns Insider

Autism Spectrum Disorder Market to Reach USD 4.07 Billion by 2033, Driven by Rising Awareness, Early Diagnosis & Advances in Personalized Therapeutics | SNS Insider

12/07/2025 08:43 AM • The global Autism Spectrum Disorder market is projected to grow from USD 2.06 billion in 2025 to USD 4.07 billion by 2033, driven by increasing awareness, early diagnosis, and advances in personalized therapeutics, with a CAGR of 8.89%.

REGMY - Collaborated on successful clinical trial and submitted Biologics License Application for telitacicept in IgA Nephropathy
RHHBY - Initiated collaborative research program to identify genetic markers for ASD subtypes, aiming to enhance diagnostic precision

#Autism Spectrum Disorder #Market Growth #Therapeutics #Early Diagnosis #Personalized Treatment

US Stormwater Management Market Size Worth USD 15.05 Billion by 2033 | SNS Insider

GlobeNewswire Inc. • Sns Insider

US Stormwater Management Market Size Worth USD 15.05 Billion by 2033 | SNS Insider

12/07/2025 08:00 AM • The U.S. Stormwater Management Market is projected to grow from $8.25 billion in 2025 to $15.05 billion by 2033, driven by environmental regulations, infrastructure upgrades, urbanization, and increasing adoption of green stormwater solutions.

WMS - Actively participating in market research and survey about flooding concerns, indicating proactive market engagement

#stormwater management #green infrastructure #urban design #environmental sustainability #infrastructure

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

GlobeNewswire Inc. • Alx Oncology Holdings Inc.

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

12/07/2025 08:00 AM • ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.

ALXO - Demonstrated strong clinical trial results with high complete response rates, promising efficacy of their lead therapeutic candidate evorpacept, and positive outlook for future development

#evorpacept #non-Hodgkin lymphoma #clinical trial #immunotherapy #CD47

Energy Trading & Risk Management Market Size to Hit $61.59 Billion by 2033 | Report by SNS Insider

GlobeNewswire Inc. • Sns Insider

Energy Trading & Risk Management Market Size to Hit $61.59 Billion by 2033 | Report by SNS Insider

12/07/2025 08:00 AM • The ETRM market is projected to grow from USD 41.06 billion in 2025 to USD 61.59 billion by 2033, driven by cloud-based solutions, renewable energy expansion, and increasing market volatility in energy trading.

SAP - Mentioned as a market player without specific details about recent innovations or performance

#energy trading #risk management #cloud computing #renewable energy #market analytics

$Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma$

GlobeNewswire Inc. • Genmab A/S

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

12/07/2025 07:50 AM • Genmab announced positive Phase 3 trial results for EPKINLY, demonstrating significant clinical benefits in treating relapsed or refractory follicular lymphoma when combined with rituximab and lenalidomide, reducing disease progression risk by 79% and achieving a 95% overall response rate.

GMAB - Successful Phase 3 trial results, FDA approval, significant clinical efficacy demonstrated in treating follicular lymphoma

#follicular lymphoma #bispecific antibody #cancer treatment #clinical trial #immunotherapy

Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA

GlobeNewswire Inc. • Pixalate

Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA

12/07/2025 12:00 AM • Pixalate's research reveals 1,248 APAC-registered mobile apps likely violating COPPA privacy regulations, potentially impacting 117 million child app users in the USA, with significant data transmission and privacy policy deficiencies.

GOOG - Ad Exchange appeared in 45% of apps identified as likely non-compliant under COPPA

#COPPA #children's privacy #mobile apps #data privacy #app stores

CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 05:34 PM • Rosen Law Firm is investigating potential securities claims for America's Car-Mart shareholders after the company reported a significant first-quarter loss and stock price decline.

NVO - Mentioned in comparison to other obesity treatments, but no direct impact on their performance from this specific trial
CRMT - Stock dropped 18.2% after reporting a first-quarter loss of 69 cents per share, compared to a 15 cents per share loss in the previous year, indicating deteriorating financial performance

#securities claims #investor losses #class action #stock performance

DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

GlobeNewswire Inc. • Rosen Law Firm

DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

12/06/2025 04:39 PM • Rosen Law Firm alerts DexCom investors about a securities class action lawsuit alleging unauthorized design changes to glucose monitoring systems that potentially compromised device reliability and user safety.

DXCM - Lawsuit claims the company made unauthorized design changes to G6 and G7 continuous glucose monitoring systems, potentially creating health risks and exposing the company to regulatory scrutiny, legal challenges, and reputational damage

#securities #class action #FDA #glucose monitoring #investor rights

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP

12/06/2025 03:51 PM • Rosen Law Firm is investigating potential securities claims for Inspire Medical Systems investors who purchased stock between August 6, 2024 and August 4, 2025, alleging misrepresentation about their sleep apnea device Inspire V's market demand and launch readiness.

INSP - The lawsuit suggests the company misrepresented key facts about their product's market demand and launch preparedness, potentially misleading investors and causing financial damages

#securities class action #investor rights #sleep apnea device #stock lawsuit

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 02:55 PM • Rosen Law Firm is investigating potential securities claims for Alvotech shareholders following an FDA Complete Response Letter for their Biologics License Application, which caused a significant stock price drop.

SOXX - Semiconductor stocks tracked by the ETF dropped 7.4% for the week
ALVO - The company received a Complete Response Letter from FDA for AVT05, resulting in a 34% stock price drop on November 3, 2025, and an additional 4% decline on November 4, 2025. The FDA noted unresolved deficiencies in their manufacturing facility inspection, indicating significant regulatory challenges.

#securities claims #FDA #Biologics License Application #stock price #investor losses

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

GlobeNewswire Inc. • Usa News Group

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

12/06/2025 01:51 PM • Market intelligence report highlighting five undervalued companies across biotech, AI, defense, gold exploration, and medical technology sectors, suggesting significant potential for valuation growth due to technological innovations and strategic positioning.

AMD - Experienced significant stock price decline as part of broader AI stock selloff
ONCY - Developing innovative cancer immunotherapy with promising Phase 3 trial design, FDA alignment, and partnerships with major pharmaceutical companies

#biotech #AI #defense technology #gold exploration #medical diagnostics #small-cap investing

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 01:36 PM • Rosen Law Firm is investigating potential securities claims for agilon health shareholders after the company suspended its 2025 financial guidance, causing a 51.5% stock price drop on August 5, 2025.

PLTR - Dropped as part of the broader technology and AI stock market decline
AGL - Company suspended full-year financial guidance, acknowledged more severe industry headwinds than previously expected, and experienced a significant 51.5% stock price decline

#securities claims #investor losses #financial guidance #stock price drop

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—WBD, TRUE, CMA, and FITB

GlobeNewswire Inc. • Juan Monteverde

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—WBD, TRUE, CMA, and FITB

12/06/2025 01:00 PM • Law firm Monteverde & Associates is investigating several corporate mergers and acquisitions, including transactions involving Warner Bros. Discovery, trueCar, Comerica, and Fifth Third Bancorp.

WBD - Potential sale to Netflix with defined share and cash exchange terms

#mergers #acquisitions #shareholder #class action #investigation

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—TBHC, BLFY, SOUL, and SNCR

GlobeNewswire Inc. • Juan Monteverde

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—TBHC, BLFY, SOUL, and SNCR

12/06/2025 01:00 PM • Law firm Monteverde & Associates is investigating several corporate mergers involving technology, banking, and acquisition companies, offering shareholders potential legal recourse.

TBHC - Proposed sale to Bed Bath & Beyond with defined stock exchange ratio

#merger #shareholder #class action #investigation

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

GlobeNewswire Inc. • Reed Kathrein

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

12/06/2025 12:58 PM • Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.

ATYR - Stock collapsed 83% after drug trial failure, facing lawsuit alleging misleading investors about drug efficacy, potential securities law violations

#securities lawsuit #drug trial #pharmaceutical #investor rights #clinical trial

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 12:53 PM • Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused a significant stock price drop.

TNDM - Company issued a voluntary medical device correction for t:slim X2 insulin pumps that triggered a 19.9% stock price decline, indicating potential product reliability issues and investor concern

#securities claim #medical device #stock drop #investor losses

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

GlobeNewswire Inc. • Prelude Therapeutics

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

12/06/2025 11:00 AM • Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.

AMZN - Dropped as a major customer, perceived as focusing on cost-cutting rather than comprehensive employee benefits
PRLD - Company presented promising preclinical data for two novel therapeutic approaches, completed toxicology studies, and is on track to file an IND in Q1 2026, indicating strong scientific progress and potential for innovative treatments

#myeloproliferative neoplasms #JAK2V617F #precision oncology #targeted therapy #antibody drug conjugate

Why Bloom Energy Stock Sank 17.3% In November

The Motley Fool • Brett Schafer

Why Bloom Energy Stock Sank 17.3% In November

12/06/2025 10:37 AM • Bloom Energy experienced a stock decline in November due to broader AI sector sentiment shifts, despite strong growth potential in AI infrastructure energy solutions and a significant Brookfield partnership.

BE - Stock fell 17.3% in November but shows recovery potential; has strong revenue growth (129% in 5 years) but considered overvalued with thin profit margins

#fuel cell #AI infrastructure #energy technology #electricity generation

Can Home Depot (HD) Stock Rebound in 2026?

The Motley Fool • Jennifer Saibil

Can Home Depot (HD) Stock Rebound in 2026?

12/06/2025 10:35 AM • Home Depot is experiencing challenges due to a suppressed real estate market and reduced consumer discretionary spending, with declining sales and earnings. Despite these challenges, the company is focusing on internal improvements and maintaining its dividend.

PFE - Initiated the challenge against BridgeBio's advertising claims through proper regulatory channels
HD - Stock is down 17% year-to-date, experiencing sales and earnings pressure due to high interest rates and reduced consumer spending on home improvement products. Management lowered full-year expectations for comparable sales and operating margin.

#home improvement #real estate market #discretionary spending #dividend #market share

Here's Why Shares in This Nvidia Partner Soared This Week

The Motley Fool • Lee Samaha

Here's Why Shares in This Nvidia Partner Soared This Week

12/06/2025 10:33 AM • Synopsys stock rose 11.7% after announcing an expanded strategic partnership with Nvidia, which involved a $2 billion investment. The partnership aims to enhance chip design and engineering simulation capabilities across multiple industries.

SNPS - Stock rose 11.7% due to strategic partnership with Nvidia, $2 billion investment, and potential expansion of total addressable market through Ansys acquisition

#AI #chip design #semiconductor #partnership #investment

PRGO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

GlobeNewswire Inc. • Robbins Geller Rudman & Dowd Llp

PRGO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

12/06/2025 09:50 AM • Perrigo faces class action lawsuit alleging misleading statements about its infant formula business acquisition, with claims of significant underinvestment, manufacturing deficiencies, and overstated financial results.

BBAI.WS - Stock down 21.2%, negative earnings of $450 million in last 12 months, sales decreased 18.4% year-over-year, high price-to-sales ratio of over 13
PRGO - Multiple disclosures of financial challenges, including 50% earnings decline, significant remediation costs, reduced sales, decreased gross margins, and strategic review of infant formula business indicating substantial operational and financial problems

#securities fraud #infant formula #class action lawsuit #investor alert

System Infrastructure Software Market to Reach USD 297.18 Billion by 2032, Growing at a CAGR of 7.12% | Research by SNS Insider

GlobeNewswire Inc. • Sns Insider

System Infrastructure Software Market to Reach USD 297.18 Billion by 2032, Growing at a CAGR of 7.12% | Research by SNS Insider

12/06/2025 09:45 AM • The system infrastructure software market is projected to grow from USD 161 billion in 2023 to USD 297.18 billion by 2032, driven by cloud adoption, digital transformation, and increasing demand for scalable IT management solutions.

PLTR - Mentioned in article but no specific negative or positive analysis provided
AMZN - Expanding collaboration with NVIDIA to enhance generative AI infrastructure, indicating technological leadership and innovation

#system infrastructure software #cloud computing #digital transformation #multi-cloud strategy #IT management

META, NFLX, CRM, And More: 5 Stocks That Dominated Investor Buzz This Week

Benzinga • Rishabh Mishra

META, NFLX, CRM, And More: 5 Stocks That Dominated Investor Buzz This Week

12/06/2025 09:30 AM • Retail investors focused on five tech stocks this week, driven by earnings reports, AI developments, and corporate news across social networking, software, streaming, and automotive sectors.

META - Faced EU antitrust probe but made strategic moves in AI, with budget cuts to metaverse and hiring Apple designer

#earnings #AI #tech stocks #retail investors #market trends

ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights

12/06/2025 08:53 AM • A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod, with investors having until December 8, 2025 to apply as lead plaintiff.

ATYR - The lawsuit alleges the company made materially false statements about their drug's capabilities, potentially misleading investors and causing artificial inflation of stock prices

#class action #lawsuit #securities #pharmaceutical #investor rights

CBD Nutraceuticals Market Projected to Reach USD 39.06 Billion by 2032 at 16.38% CAGR – SNS Insider

GlobeNewswire Inc. • Sns Insider

CBD Nutraceuticals Market Projected to Reach USD 39.06 Billion by 2032 at 16.38% CAGR – SNS Insider

12/06/2025 08:45 AM • The CBD nutraceuticals market is projected to grow from $9.75 billion in 2023 to $39.06 billion by 2032, driven by increasing consumer interest in natural wellness solutions and gradual product legalization.

CVSI - Acquired Elevated Softgels LLC, enhancing global presence in CBD nutraceuticals industry

#CBD #nutraceuticals #wellness #natural health #market growth